Year-end Sale % OFF 
Abstract
Glioma is the most common primary intracranial malignant tumor in adults. Although there have been many efforts on potential targeted therapy of glioma, the patient’s prognosis remains dismal. Methyltransferase Like 7B (METTL7B) has been found to affect the development of a variety of tumors. In this study, we collected RNA-seq data of glioma in CGGA and TCGA, analyzed them separately. Then, Kaplan-Meier survival analysis, univariate and multivariate Cox analysis, and receiver operating characteristic curve (ROC curve) analysis were used to evaluate the effect of METTL7B on prognosis. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Set Enrichment Analysis (GSEA) enrichment analyses were used to identify the function or pathway associated with METTL7B. Moreover, the ESTIMATE algorithm, Cibersort algorithm, Spearman correlation analysis, and TIMER database were used to explore the relationship between METTL7B and immunity. Finally, the role of METTL7B was explored in glioma cells. We found that METTL7B is highly expressed in glioma, and high expression of METTL7B in glioma is associated with poor prognosis. In addition, there were significant differences in immune scores and immune cell infiltration between the two groups with different expression levels of METTL7B. Moreover, METTL7B was also correlated with immune checkpoints. Knockdown of METTL7B revealed that METTL7B promoted the progression of glioma cells. The above results indicate that METTL7B affects the prognosis of patients and is related to tumor immunity, speculating that METTL7B may be a new immune-related target for the treatment of glioma.
Highlights
Glioma is the most common primary malignant brain tumor in adults [1, 2]
We analyzed the differential genes between the two groups with high and low expression of Methyltransferase Like 7B (METTL7B) and performed enrichment analysis based on the differential genes, and the results indicated enrichment of several immune-related functions and pathways
The expression of METTL7B in tumor samples of glioma and normal samples was evaluated using the GEPIA website and we found that METTL7B is highly expressed in both LGG and GBM samples (Figure 1A)
Summary
Glioma is the most common primary malignant brain tumor in adults [1, 2]. Glioma can be divided into low grade glioma (WHO grade II/III, LGG) and glioblastoma (WHO grade IV, GBM) [3]. WHO 2016 classified glioma according to molecular pathological type (IDH mutation and 1p/19q Codeletion), which will be helpful for clinical treatment [4, 5]. Surgery, METTL7B in Glioma radiotherapy, and alkylating agent are the main treatment options for glioma [6,7,8]. Recent studies find that tumor immune response plays an essential role in glioma [11,12,13], suggesting the promising prospect of immune therapy for glioma therapy
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
